Edition:
United Kingdom

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

25.36EUR
14 Aug 2018
Change (% chg)

€0.46 (+1.85%)
Prev Close
€24.90
Open
€24.84
Day's High
€25.50
Day's Low
€24.84
Volume
27,953
Avg. Vol
63,373
52-wk High
€30.00
52-wk Low
€18.34

Latest Key Developments (Source: Significant Developments)

Cellectis Operating Loss Widens To 21.7 Million US Dollars
Wednesday, 1 Aug 2018 

Aug 2 (Reuters) - CELLECTIS SA ::SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO.Q2 OPERATING LOSS $21.7 MLN VS $19.9 MLN YEAR AGO.Q2 NET LOSS $9.7 MLN VS $26.5 MLN YEAR AGO.END-H1 CASH POSITION OF $491 MLN EXPECTED TO FUND OPERATIONS UNTIL 2022.  Full Article

Calyxt Announces Upsizing And Pricing Of Follow-On Offering
Friday, 18 May 2018 

May 18 (Reuters) - Calyxt Inc ::CALYXT ANNOUNCES UPSIZING AND PRICING OF FOLLOW-ON OFFERING.CALYXT - PRICE OF FOLLOW-ON PUBLIC OFFERING OF 3.6 MILLION SHARES OF COMMON STOCK LAUNCHED MAY 15 HAS BEEN SET AT $15.00 PER SHARE.CALYXT INC - OFFERING WAS UPSIZED FROM 3.1 MILLION SHARES TO ACCOMMODATE CELLECTIS TO BUY 550,000 SHARES.  Full Article

Cellectis Qtrly Total Revenues And Other Income $8.1 Mln Vs $10.3 Mln
Monday, 7 May 2018 

May 7 (Reuters) - Cellectis SA ::CELLECTIS SA QTRLY TOTAL REVENUES AND OTHER INCOME $8.1 MILLION VERSUS $10.3 MILLION.CELLECTIS SA QTRLY LOSS PER SHARE $0.71.CELLECTIS SA QTRLY ADJUSTED LOSS PER SHARE $0.39.  Full Article

Cellectis Announces Pricing Of Follow On Offering
Thursday, 5 Apr 2018 

April 5 (Reuters) - Cellectis SA ::CELLECTIS ANNOUNCES PRICING OF FOLLOW-ON OFFERING.‍PRICE OF ITS OFFERING OF ADS LAUNCHED ON APRIL 3, 2018, HAS BEEN SET TODAY AT $31.00/ADS AND NUMBER OF OFFERED ADSS IS 5.6 MILLION.  Full Article

Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares
Tuesday, 3 Apr 2018 

April 4 (Reuters) - CELLECTIS SA ::ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS).EACH ADS REPRESENTS ONE ORDINARY SHARE OF CELLECTIS.TO GRANT UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL 15 PCT OF AGGREGATE OFFERING SIZE.GOLDMAN SACHS, CITIGROUP AND BARCLAYS ARE ACTING AS BOOK-RUNNING MANAGERS.NOMURA IS LEAD MANAGER, OPPENHEIMER AND LADENBURG THALMANN ARE CO-MANAGERS.  Full Article

Cellectis, Servier And Pfizer Present Preliminary Data From Two UCART19 Phase I Studies
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - CELLECTIS ::SERVIER AND PFIZER PRESENT PRELIMINARY DATA FROM UCART19 PHASE I STUDIES IN ADULT AND PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.STUDIES DEMONSTRATED SAFETY AND TOLERABILITY OF UCART19.STUDIES RESULTED IN 83-PCT COMPLETE REMISSION RATE ACROSS THE PATIENT POPULATION.IN 'CALM' TRIAL (UCART19 IN ADVANCED LYMPHOID MALIGNANCIES) FOR ADULTS, FIVE OUT OF SEVEN PATIENTS ACHIEVED MOLECULAR REMISSION AT DAY 28.'CALM' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED; CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.ONE PATIENT IN 'CALM' TRIAL DEVELOPED GRADE 4 CYTOKINE RELEASE SYNDROME AND NEUTROPENIC SEPSIS LEADING TO DEATH AT DAY 15.IN 'PALL' TRIAL (PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA) FOR CHILDREN, ALL FIVE PATIENTS ACHIEVED MOLECULAR REMISSION;.'PALL' TRIAL: ONE GRADE 1 CUTANEOUS ACUTE GVHD OCCURED; NO SEVERE NEUROTOXICITY OBSERVED.'PALL TRIAL': CYTOKINE RELEASE SYNDROMES WERE MOSTLY MANAGEABLE.  Full Article

Cellectis Appoints Stéphane Depil Senior VP Research & Development And Chief Medical Officer
Monday, 4 Dec 2017 

Dec 4 (Reuters) - CELLECTIS SA ::CELLECTIS APPOINTS IMMUNO-ONCOLOGY LEADER STÉPHANE DEPIL TO POSITION OF SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT AND CHIEF MEDICAL OFFICER.  Full Article

Cellectis says cash position at Sept. 30 of $304.1 million
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - CELLECTIS SA ::ANNOUNCED ON MONDAY: CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS AT SEPT 30 STOOD AT $304.1 MLN VS $271.2 MLN AT JUNE 30 .Q3 TOTAL REVENUES AND OTHER INCOME $7.3 MLN VS $12.6 MLN YEAR AGO.Q3 FINANCIAL LOSS $3.4 MLN VS LOSS OF $1.2 MLN YEAR AGO .Q3 NET LOSS ATTRIBUTABLE TO SHAREHOLDERS $26.2 MLN VS LOSS OF $14.1 MLN YEAR AGO.EXPECTS ITS CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS WILL BE SUFFICIENT TO FUND ITS CURRENT OPERATIONS INTO 2020.  Full Article

Fda lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Cellectis SA :FDA lifts clinical hold on cellectis phase 1 clinical trials with UCART123 in AML and BPDCN.Says ‍working with investigators and clinical sites to obtain IRB'S approval on revised protocols and resume patient enrollment​.Cellectis SA says ‍agreed with FDA to decrease of cohort dose level to 6.25x10(4) UCART123 cells/ in Phase 1 UCART123 protocols​.  Full Article

Cellectis Announces the Issuance of US Patent 9,458,439
Wednesday, 5 Oct 2016 

Cellectis SA : Announced on Tuesday the issuance of U.S. patent 9,458,439 – which claims gene inactivation by use of chimeric restriction endonucleases .This patent granted by the USPTO to the Institut Pasteur and Boston Children's Hospital naming Dr Andre Choulika and Pr. Richard C. Mulligan as co-inventors, is exclusively licensed to Cellectis.  Full Article

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO